{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:17:20Z","timestamp":1792621040106,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing the blood flow rate (BFR) is a useful method for increasing Kt\/V and the clearance for low molecular solutes. Hemodialysis patients are often anemic due to hypoerythropoiesis and their chronic inflammatory state. Hepcidin, a hormone that regulates iron homeostasis, is considered as an indicator of iron deficiency in patients with end-stage renal disease. This study aimed to investigate the effects of an increased BFR during hemodialysis on serum hepcidin levels and anemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between April 2014 and March 2016, 22 chronic dialysis patients (11 men [50.0\u2009%]; mean [\u00b1\u2009standard deviation] age, 72\u2009\u00b1\u200912 years) undergoing maintenance hemodialysis treatment, thrice weekly, were enrolled and followed prospectively for 24 months. In April 2014, the BFR was 200 mL\/min; in April 2015 this was increased to 400 mL\/min, which was within acceptable limits. The dialysate flow rate remained stable at; 500mlL\/min. Blood samples were collected in March 2015 and 2016. The primary endpoint was the comparison of the amounts of erythropoiesis-stimulating agent (ESA) required.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The increased BFR increased the Kt\/V and contributed to significantly decreased urea nitrogen (UN) (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) and creatinine (Cr) (<jats:italic>p<\/jats:italic>\u2009=\u20090.005) levels. The dialysis efficiency was improved by increasing the BFR. Ferritin (<jats:italic>p<\/jats:italic>\u2009=\u20090.038), hepcidin (<jats:italic>p<\/jats:italic>\u2009=\u20090.041) and high-sensitivity interleukin-6 (<jats:italic>p<\/jats:italic>\u2009=\u20090.038) levels were also significantly reduced. The ESA administered was significantly reduced (<jats:italic>p<\/jats:italic>\u2009=\u20090.004) and the Erythropoietin Resistant Index (ERI) significantly improved (<jats:italic>p<\/jats:italic>\u2009=\u20090.031). The reduction rates in UN (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), Cr (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and beta-2 microglobulin (<jats:italic>p<\/jats:italic>\u2009=\u20090.017) levels were significantly greater post the BFR increase compared to those prior to the BFR increase. However, hepcidin was not affected by the BFR change.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Increasing BFR was associated with hemodialysis efficiency, and led to reduce inflammatory cytokine interleukin-6, but did not contribute to reduce C-reactive protein. This reduced hepcidin levels, ESA dosage and ERI. Hepcidin levels were significantly correlated with ferritin levels, and it remains to be seen whether reducing hepcidin leads to improve ESA and iron availability during anemia management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02426-7","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T01:02:36Z","timestamp":1623718956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Masateru","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sumimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ohdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"issue":"2","key":"2426_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/ki.1996.348","volume":"50","author":"PJ Held","year":"1996","unstructured":"Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, et al. The dose of hemodialysis and patient mortality. Kidney Int. 1996;50(2):550\u20136.","journal-title":"Kidney Int"},{"issue":"9","key":"2426_CR2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/ki.2009.307","volume":"76","author":"FO Finkelstein","year":"2009","unstructured":"Finkelstein FO, Wuerth D, Finkelstein SH. Health related quality of life and the CKD patient: challenges for the nephrology community. Kidney Int. 2009;76(9):946\u201352.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"2426_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000490960","volume":"139","author":"SJ MacNeill","year":"2018","unstructured":"MacNeill SJ, Ford D, Evans K, Medcalf JF. Chapter 2 UK Renal Replacement Therapy Adult Prevalence in 2016: National and Centre-specific Analyses. Nephron. 2018;139 Suppl 1:47\u201374.","journal-title":"Nephron"},{"issue":"11","key":"2426_CR4","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1093\/ndt\/gfs021","volume":"27","author":"F Tentori","year":"2012","unstructured":"Tentori F, Zhang J, Li Y, Karaboyas A, Kerr P, Saran R, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2012;27(11):4180\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2426_CR5","first-page":"24","volume":"13","author":"G Hamilton","year":"2003","unstructured":"Hamilton G, Locking-Cusolito H. Hemodialysis adequacy and quality of life: how do they relate? Cannt j. 2003;13(4):24\u20139.","journal-title":"Cannt j"},{"issue":"1","key":"2426_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmet.2008.06.009","volume":"8","author":"MU Muckenthaler","year":"2008","unstructured":"Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab. 2008;8(1):1\u20133.","journal-title":"Cell Metab"},{"issue":"3","key":"2426_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1744-9987.2010.00836.x","volume":"14","author":"Y Tsubakihara","year":"2010","unstructured":"Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010;14(3):240\u201375.","journal-title":"Ther Apher Dial"},{"issue":"1","key":"2426_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1744-9987.12071","volume":"18","author":"A Tanaka","year":"2014","unstructured":"Tanaka A, Kato A, Suzuki Y, Suzuki M, Ohmori H, Sumimoto R, et al. Association of increased indoleamine 2, 3-dioxygenase with impaired natural killer cell activity in hemodialysis patients. Ther Apher Dial. 2014;18(1):19\u201323.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"2426_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0272-6386(12)70317-7","volume":"22","author":"JT Daugirdas","year":"1993","unstructured":"Daugirdas JT. Linear estimates of variable-volume, single-pool Kt\/V: an analysis of error. Am J Kidney Dis. 1993;22(2):267\u201370.","journal-title":"Am J Kidney Dis"},{"key":"2426_CR10","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-G\u00f3mez JM, Portol\u00e9s JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008(111):S75-81.","DOI":"10.1038\/ki.2008.523"},{"issue":"4","key":"2426_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.5301\/jn.5000234","volume":"26","author":"S Singh","year":"2013","unstructured":"Singh S, Choi P, Power A, Ashby D, Cairns T, Griffith M, et al. Ten-year patient survival on maintenance haemodialysis: association with treatment time and dialysis dose. J Nephrol. 2013;26(4):763\u201370.","journal-title":"J Nephrol"},{"issue":"3","key":"2426_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/hdi.12142","volume":"18","author":"N Kimata","year":"2014","unstructured":"Kimata N, Karaboyas A, Bieber BA, Pisoni RL, Morgenstern H, Gillespie BW, et al. Gender, low Kt\/V, and mortality in Japanese hemodialysis patients: opportunities for improvement through modifiable practices. Hemodial Int. 2014;18(3):596\u2013606.","journal-title":"Hemodial Int"},{"issue":"10","key":"2426_CR13","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s11255-019-02268-1","volume":"51","author":"V Kousoula","year":"2019","unstructured":"Kousoula V, Georgianos PI, Mavromatidis K, Syrganis C, Thodis E, Panagoutsos S, et al. Reversed connection of cuffed, tunneled, dual-lumen catheters with increased blood flow rate maintains the adequacy of delivered dialysis despite the higher access recirculation. Int Urol Nephrol. 2019;51(10):1841\u20137.","journal-title":"Int Urol Nephrol"},{"key":"2426_CR14","unstructured":"Health AAMARCf. Arbor Research Collaborative for Health. DOPPS practice monitor, c2020 [cited 2019 Aug 19]"},{"issue":"1","key":"2426_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1073-4449(99)70011-7","volume":"6","author":"RA Ward","year":"1999","unstructured":"Ward RA. Blood flow rate: an important determinant of urea clearance and delivered Kt\/V. Adv Ren Replace Ther. 1999;6(1):75\u20139.","journal-title":"Adv Ren Replace Ther"},{"issue":"11","key":"2426_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/clc.4960161108","volume":"16","author":"O Alfurayh","year":"1993","unstructured":"Alfurayh O, Galal O, Sobh M, Fawzy M, Taher S, Qunibi W, et al. The effect of extracorporeal high blood flow rate on left ventricular function during hemodialysis\u2013an echocardiographic study. Clin Cardiol. 1993;16(11):791\u20135.","journal-title":"Clin Cardiol"},{"issue":"4","key":"2426_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1542-4758.2007.00212.x","volume":"11","author":"HS Trivedi","year":"2007","unstructured":"Trivedi HS, Kukla A, Prowant B, Lim HJ. A study of the extracorporeal rate of blood flow and blood pressure during hemodialysis. Hemodial Int. 2007;11(4):424\u20139.","journal-title":"Hemodial Int"},{"issue":"1","key":"2426_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1542-4758.2006.01178.x","volume":"10","author":"JP Bosch","year":"2006","unstructured":"Bosch JP, Lew SQ, Barlee V, Mishkin GJ, von Albertini B. Clinical use of high-efficiency hemodialysis treatments: long-term assessment. Hemodial Int. 2006;10(1):73\u201381.","journal-title":"Hemodial Int"},{"issue":"6","key":"2426_CR19","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","volume":"65","author":"AK Cheung","year":"2004","unstructured":"Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004;65(6):2380\u20139.","journal-title":"Kidney Int"},{"issue":"10","key":"2426_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1681\/ASN.V9101940","volume":"9","author":"WM McClellan","year":"1998","unstructured":"McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol. 1998;9(10):1940\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"5704","key":"2426_CR21","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090\u20133.","journal-title":"Science"},{"key":"2426_CR22","doi-asserted-by":"publisher","first-page":"3041738","DOI":"10.1155\/2020\/3041738","volume":"2020","author":"MF Yacoub","year":"2020","unstructured":"Yacoub MF, Ferwiz HF, Said F. Effect of Interleukin and Hepcidin in Anemia of Chronic Diseases. Anemia. 2020;2020:3041738.","journal-title":"Anemia"},{"issue":"4","key":"2426_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1182\/blood-2005-10-4043","volume":"108","author":"N Tomosugi","year":"2006","unstructured":"Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108(4):1381\u20137.","journal-title":"Blood"},{"key":"2426_CR24","doi-asserted-by":"publisher","first-page":"329646","DOI":"10.1155\/2010\/329646","volume":"2010","author":"N Campostrini","year":"2010","unstructured":"Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:329646.","journal-title":"J Biomed Biotechnol"},{"issue":"9","key":"2426_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/eurjhf\/hfq099","volume":"12","author":"K van der Putten","year":"2010","unstructured":"van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease\/chronic heart failure patients. Eur J Heart Fail. 2010;12(9):943\u201350.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2426_CR26","doi-asserted-by":"publisher","first-page":"e39783","DOI":"10.1371\/journal.pone.0039783","volume":"7","author":"NC van der Weerd","year":"2012","unstructured":"van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One. 2012;7(7):e39783.","journal-title":"PLoS One"},{"issue":"10","key":"2426_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1365-2362.2009.02182.x","volume":"39","author":"G Weiss","year":"2009","unstructured":"Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39(10):883\u201390.","journal-title":"Eur J Clin Invest"},{"issue":"25","key":"2426_CR28","doi-asserted-by":"publisher","first-page":"e218-25","DOI":"10.1182\/blood-2011-02-337907","volume":"117","author":"TE Galesloot","year":"2011","unstructured":"Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117(25):e218-25.","journal-title":"Blood"},{"issue":"1","key":"2426_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0272-6386(99)70259-3","volume":"33","author":"J Gunnell","year":"1999","unstructured":"Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33(1):63\u201372.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2426_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1056\/NEJM199602153340702","volume":"334","author":"O Ifudu","year":"1996","unstructured":"Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996;334(7):420\u20135.","journal-title":"N Engl J Med"},{"issue":"1","key":"2426_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MCO.0000000000000342","volume":"20","author":"GJ Ko","year":"2017","unstructured":"Ko GJ, Obi Y, Tortorici AR, Kalantar-Zadeh K. Dietary protein intake and chronic kidney disease. Curr Opin Clin Nutr Metab Care. 2017;20(1):77\u201385.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"2426_CR32","first-page":"13","volume":"109","author":"JS Koenig","year":"1997","unstructured":"Koenig JS, Fischer M, Bulant E, Tiran B, Elmadfa I, Druml W. Antioxidant status in patients on chronic hemodialysis therapy: impact of parenteral selenium supplementation. Wien Klin Wochenschr. 1997;109(1):13\u20139.","journal-title":"Wien Klin Wochenschr"},{"issue":"10","key":"2426_CR33","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1093\/ndt\/gfq859","volume":"26","author":"Y Fujishima","year":"2011","unstructured":"Fujishima Y, Ohsawa M, Itai K, Kato K, Tanno K, Turin TC, et al. Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrol Dial Transplant. 2011;26(10):3331\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2426_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lfs.2015.12.028","volume":"145","author":"A Gugliandolo","year":"2016","unstructured":"Gugliandolo A, Gangemi C, Calabr\u00f2 C, Vecchio M, Di Mauro D, Renis M, et al. Assessment of glutathione peroxidase-1 polymorphisms, oxidative stress and DNA damage in sensitivity-related illnesses. Life Sci. 2016;145:27\u201333.","journal-title":"Life Sci"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02426-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02426-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02426-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T01:03:02Z","timestamp":1623718982000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02426-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02426-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"assertion":[{"value":"29 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each participating patient, and the study protocol was approved by the local ethics committee according to the 2008 revision of the Declaration of Helsinki. This study was the approved by the Institutional Review Board of National Hospital Organization Yanai Medical Center (Provided ID Number: Y-27-14) on the basis of the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare in Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not appliable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}